Quotient Clinical Announces New Investment In Translational Pharmaceutics™
News Nov 19, 2013
This investment is a direct response to the rapid rate of adoption of the Company’s Translational Pharmaceutics platform and unique approach by a growing international client base.
Translational Pharmaceutics integrates formulation development, real-time manufacturing and clinical testing to offer shorter timelines, reduced costs and increased success rates in early phase drug development. The 25,000 ft2 expansion allows the extension of both the Pharmaceutical Development Laboratory and the Clinical Pharmacology Unit, which now has 85 beds and is accredited for all types of early clinical development programmes by the MHRA. The Company has also invested in spray-drying formulation and manufacturing capabilities – to address the development challenges of poorly soluble drugs – and established an in silico modelling group to support biopharmaceutical customers in defining formulation strategies and assessing in vitro-in vivo correlations (IVIVCs).
Mark Egerton, CEO of Quotient Clinical, commented: “Improving R&D productivity requires an evolution of traditional drug development processes. Our customers are attracted to our Translational Pharmaceutics platform to improve the efficiency of their early development programmes, and this latest round of investment enables us to extend our platform while continuing to offer rapid project start times.”
Many life-saving medicines, including insulin, antibodies and vaccines, are derived from living cells. These “biologics” can be difficult to obtain and store on the battlefield or in remote areas. That’s why scientists are trying to develop portable systems that can quickly manufacture small batches of protein therapeutics on demand.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019